Literature DB >> 10491891

[A short praziquantel regimen for the treatment of parenchymatous neurocysticercosis].

T Corona1, R Lugo, R Medina, J Sotelo.   

Abstract

OBJECTIVE: Fifteen-day praziquantel therapy for parenchymal neurocysticercosis has been shown to be effective. Plasma and cerebrospinal fluid concentrations of praziquantel peak two hours after administration. Maintenance of high concentrations of the drug for six hours may be an adequate therapy for the disease.
METHODS: Thirty patients with parenchymal neurocysticercosis were treated with three oral doses of praziquantel(25 mg/kg) at two-hour intervals. Intramuscular dexamethasone (10 mg/day) was administered for three days after the praziquantel treatment.
RESULTS: Cysts disappeared in 21 patients and showed a decrease in number of 30 to 60% in seven patients. Two patients remained without change. Considering the total number of cysts, this therapy showed a 70.7% eradication rate. Two patients had seizures, six reported headache, and nausea was frequently reported. Patients under antiepileptic treatment did not have seizures.
CONCLUSION: The cost and duration of treatment with praziquantel were significantly reduced and the inflammation that follow the destruction of the parasite was treated sequentially.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491891

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  2 in total

Review 1.  Neurocysticercosis--New Millennium, ancient disease and unending debate.

Authors:  G Narula; K S Bawa
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

Review 2.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.